Compare Ascendis Pharma A/S (ASND) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs T Rowe Price Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while T Rowe Price Group Inc trades at $118.55 (market cap $25.40B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.39% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TROW | |
|---|---|---|
Market Cap | $17.74B | $25.40B |
Sector | Health | Financials |
52-Week High | $277.18 | $120.16 |
52-Week Low | $163.32 | $86.19 |
Enterprise Value | $18.11B | $22.11B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
T. Rowe Price (TROW) trades at $118.55, up 1.28% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.28% net income margin and a P/E of 12.72, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow, supporting a sustainable dividend. Strategic enhancements to its institutional business and positive media coverage highlight ongoing growth initiatives.
The outlook for TROW is positive, driven by solid fundamentals and strategic positioning, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in asset management. Upside potential exists if the company continues to exceed earnings estimates and manage equity outflows effectively, but macroeconomic volatility remains a key risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
